Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook

doi:10.21037/atm-21-2804

科研成果详情

题名	Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
作者	Jin, Zixian 1,2; Shen, Jianfei1,2; Wang, Chunguo 1,2; Chen, Dong1,2; Zhang, Bo 1,2; Zhang, Jian 1,2; Ajani, Jaffer A.4; Bennouna, Jaafar 5,6; Chao, Joseph 7; Yoon, Harry H.8; Zhu, Hongyu 1,2; Ruan, Yuhang 1,2; Zhu, Chengchu1,2; Xu, Anyi 1,3
发表日期	2021-07
发表期刊	ANNALS OF TRANSLATIONAL MEDICINE 影响因子和分区
语种	英语
原始文献类型	Review
关键词	Esophageal cancer (EC) pembrolizumab programmed death-ligand 1 (PD-1) programmed cell death protein 1 (PD-L1) immune checkpoint inhibitors
其他关键词	NEOADJUVANT CHEMORADIOTHERAPY ; PD-1 ; CHEMOTHERAPY ; CARCINOMA ; THERAPY ; BIOMARKERS ; PATHWAY ; LIGAND
摘要	Objective: Based on the current evidence, review the efficacy and safety profile of pembrolizumab, along with its shortcomings, in an effort to define future research directions. Background: The survival outcome of esophageal cancer (EC) is poor, especially in patients with advanced stage. Palliative surgery, chemotherapy, radiotherapy and chemoradiotherapy have limited efficacy in prolonging the survival time. Currently, immunotherapies, including adoptive cell therapy-based, antibody based, and vaccine-based therapies, are attracting considerable attention. The mechanism of immunotherapy lies in the modification of immune response and prevention of immune escape. Immunomodulatory agents can block the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway, thereby allowing lymphocytes to attack tumor cells. This class of drugs has the potential to treat a variety of tumors and may substantially improve overall survival (OS) in some patients. Multiple clinical trials have shown that pembrolizumab has good efficacy and safety, enhances the EC treatment paradigm, and has even become the first-line treatment of choice for patients with PD-L1-positive recurrent or metastatic EC. Methods: We reviewed the results of clinical trials of pembrolizumab for EC and gastroesophageal cancer presented at Embase, PubMed, the American Society of Clinical Oncology (ASCO) annual meetings, and the Cochrane Central Register of Controlled Trials. Conclusions: Pembrolizumab has good efficacy and tolerability profiles, and has emerged as a second-line option for the treatment of PD-L1-positive locally advanced or metastatic ESCC. Pembrolizumab has many promising applications, and further investigations into its mechanisms should be conducted.
出版者	AME PUBL CO
出版地	SHATIN
ISSN	2305-5839
EISSN	2305-5847
卷号	9 期号:14 页码:1189
DOI	10.21037/atm-21-2804
页数	13
WOS类目	Oncology ; Medicine, Research & Experimental
WOS研究方向	Oncology ; Research & Experimental Medicine
WOS记录号	WOS:000685431900023
收录类别	SCIE ; PUBMED
URL	查看原文
PubMed ID	34430630
PMC记录号	PMC8350624
通讯作者地址	[Zhu, Chengchu;Xu, Anyi]Key Lab Minimally Invas Tech & Rapid Rehabil Dige, Linhai, Peoples R China. ; [Zhu, Chengchu]Wenzhou Med Univ, Dept Thorac Surg, Taizhou Hosp Zhejiang Prov, Linhai 317000, Peoples R China. ; [Xu, Anyi]Wenzhou Med Univ, Dept Emergency, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China.
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20270
专题	附属第二医院_心胸外科其他_附属台州医院（浙江省台州医院）
通讯作者	Zhu, Chengchu; Xu, Anyi
作者单位	1.Key Lab Minimally Invas Tech & Rapid Rehabil Dige, Linhai, Peoples R China; 2.Wenzhou Med Univ, Dept Thorac Surg, Taizhou Hosp Zhejiang Prov, Linhai 317000, Peoples R China; 3.Wenzhou Med Univ, Dept Emergency, Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China; 4.Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; 5.Univ Hosp Nantes, Dept Med Oncol, Nantes, France; 6.Univ Nantes, CRCINA, INSERM, Nantes, France; 7.City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA; 8.Mayo Clin, Div Med Oncol, Rochester, MN USA
第一作者单位	附属第二医院_心胸外科
通讯作者单位	附属第二医院_心胸外科; 其他_附属台州医院（浙江省台州医院）
推荐引用方式 GB/T 7714	Jin, Zixian,Shen, Jianfei,Wang, Chunguo,et al. Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook[J]. ANNALS OF TRANSLATIONAL MEDICINE,2021,9(14):1189.
APA	Jin, Zixian., Shen, Jianfei., Wang, Chunguo., Chen, Dong., Zhang, Bo., ... & Xu, Anyi. (2021). Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. ANNALS OF TRANSLATIONAL MEDICINE, 9(14), 1189.
MLA	Jin, Zixian,et al."Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook".ANNALS OF TRANSLATIONAL MEDICINE 9.14(2021):1189.